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Melanoma is a highly aggressive tumour that can metastasize very early in disease pro-
gression. Notably, melanoma can disseminate using amoeboid invasive strategies. We show
here that high Myosin II activity, high levels of ki-67 and high tumour-initiating abilities are
characteristic of invasive amoeboid melanoma cells. Mechanistically, we find that WNT11-
FZD7-DAAM1 activates Rho-ROCK1/2-Myosin II and plays a crucial role in regulating
tumour-initiating potential, local invasion and distant metastasis formation. Importantly,
amoeboid melanoma cells express both proliferative and invasive gene signatures. As such,
invasive fronts of human and mouse melanomas are enriched in amoeboid cells that are also
ki-67 positive. This pattern is further enhanced in metastatic lesions. We propose eradication
of amoeboid melanoma cells after surgical removal as a therapeutic strategy.
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Malignant melanoma is one of the most aggressive can-cers responsible for more than 80% of skin cancer-related deaths. Melanoma is a non-epithelial tumour
originating in melanocytes, the pigment-producing cells derived
from the neural crest (NC). NC is a highly migratory and mul-
tipotent cell population that undergoes epithelial to mesenchymal
transition (EMT) during embryogenesis1. The highly metastatic
and therapy-resistant features of melanoma have been linked to
its NC-like phenotype with stemness properties1–4. Melanomas
are very heterogeneous and comprise different subpopulations of
cells with stem cell-like properties5,6. These cells are required to
initiate and sustain tumour growth, therapy resistance and sub-
sequent tumour relapse4,5.
Migratory melanoma cells display high cellular plasticity, shift-
ing between elongated and amoeboid modes of motility to adapt to
changing microenvironments7–10. Both migratory modes require
Myosin II activity to a certain extent, but amoeboid cells are
characterized by hyper-activation of Rho-ROCK1/2 signalling9–12.
ROCK1/2 activation downstream of RhoA/C results in decreased
myosin phosphatase activity and increased MLC2 phosphorylation
and Myosin II activity. Amoeboid cells migrate faster in vivo and
are enriched in the invasive fronts of primary tumours and in
secondary lesions7,10,12–16. On the other hand, in epithelial
tumours, acquisition of a migratory and invasive phenotype via
EMT has been linked to the increase in stem cell-like properties17.
In melanoma, switching from proliferative to invasive states has
been associated with melanoma progression and metastasis18,19.
Although this phenotype switching resembles an EMT-like beha-
viour, the connection with tumour-initiating abilities in melanoma
remains elusive20,21. Furthermore, whether ROCK-driven amoe-
boid invasive behaviour is associated with stem cell-like properties
is not clear.
In this study, we show how amoeboid invasive melanoma cells
with high Myosin II activity harbour tumour-initiating abilities.
We find that ROCK1/2 regulates EMT-related genes that, in
return, control amoeboid features. WNT11-FZD7-DAAM1 acti-
vates Rho-ROCK1/2-Myosin II to control tumour-initiating
potential, local invasion and distant metastasis formation. We
show that the invasive fronts of human primary melanomas are
enriched in amoeboid invading and proliferating cells expressing
non-canonical Wnt and cancer stem cell markers.
Results
Amoeboid cells support tumour initiation in melanoma
in vitro and in vivo. To explore if amoeboid melanoma cells
express genes related to NC development or stem cell-like fea-
tures, single-sample gene set enrichment analysis (ssGSEA) was
performed in a published transcriptional signature for amoeboid
melanoma cells10. Specifically, the transcriptomes of amoeboid
A375M2 melanoma cells were compared to A375M2 cells treated
with ROCK1/2 inhibitors (ROCKi) or blebbistatin, a direct
Myosin II inhibitor, or compared to intrinsically less amoeboid
and less metastatic A375P melanoma cells with lower Myosin II
activity10,12,15. ssGSEA analysis revealed that A375M2 cells were
enriched in different gene signatures that confer essential attri-
butes of stem cell-like properties, including NC genes, cancer
stem cell or embryonic stem cell signatures (Fig. 1a).
Next, we assessed the in vivo tumour-initiating potential of
limiting dilutions (500,000, 50,000 and 5,000 cells) of A375M2 and
A375P cells subcutaneously injected into immunodeficient NOD/
SCID/IL2Rγ−/− (NSG) mice and using extreme limiting dilution
analysis (ELDA)22. Amoeboid A375M2 cells were more efficient
in tumour initiation, with a significant difference in tumour-
initiating frequency (TIF) (Fig. 1b), and showed increased tumour
growth in all conditions compared to A375P cells (Fig. 1c).
Enrichment in rounded cells (Fig. 1d) and Myosin II activity, as
measured by phosphorylated MLC2 (p-MLC2) levels (Fig. 1e),
were observed at the invasive front (IF) of A375M2 tumours
compared with tumour body (TB), while decreased cell rounding
and Myosin II levels were found in A375P tumours (Fig. 1d, e).
Importantly, we also observed an increase in amoeboid features in
IFs of A375P tumours compared to TBs, although less
pronounced (Fig. 1d, e). To further investigate the heterogeneity
of Myosin II levels within the tumours, Myosin II activity was
scored from 0 (low) to 3 (very high) based on p-MLC2 intensity.
A375M2 tumours showed an increase in cells with very high
Myosin II in the IF (Supplementary Fig. 1a). High ki-67 levels
have been associated with the aggressiveness of cutaneous
melanoma23. Although no differences were observed in cell
numbers in vitro after 7 days in culture (Supplementary Fig. 1b),
A375M2 tumours showed a higher proliferation index in vivo, as
evidenced by ki-67 staining (Supplementary Fig. 1c). Interestingly,
IFs of all tumours were enriched in ki-67 proliferative cells. These
data suggest that amoeboid cells with intrinsically high Myosin II
activity are also proliferative and promote tumour initiation
in vivo.
We next investigated in vitro self-renewal capacity of melanoma
cells in low adherent conditions. We introduced another pair of
melanoma cell lines, WM983B (metastatic, rounded-amoeboid and
high Myosin II) and WM983A (primary tumour, elongated and
low Myosin II)15,24 derived from the same patient. Using these two
models, we performed serial sphere passages of elongated
melanoma cells with low levels of Myosin II12,15,24 (A375P and
WM983A) (Supplementary Fig. 1d). Serial passaging resulted in
cells with increased melanosphere formation abilities over time
(Fig. 1f). Although tumour-initiating cells are described to be in a
slow proliferative state25, sub-populations of proliferating stem
cells have also been found in some tumours26. Immunohisto-
chemical analysis of melanospheres revealed an increase in Myosin
II activity (Fig. 1g) and higher percentage of ki-67 positive cells
(Fig. 1h) with increasing passage number. Morphology of cells
from adherent conditions and of dissociated single cells from
serially passaged spheres was also assessed on collagen I matrices to
recapitulate the dermal environment7,8,10,12,14. Importantly, serial
passages resulted in an enrichment of rounded cells (Fig. 1i) with
high Myosin II levels (Fig. 1j) and increased blebbing (Fig. 1k).
Increased self-renewal ability was, therefore, associated with
increased amoeboid features. Although the enrichments were less
pronounced, similar results were obtained when serial sphere
passages were performed in cells in an already amoeboid
phenotype (A375M2 and WM983B) (Supplementary Fig. 1e–j).
Moreover, MLC2-GFP was transduced into WM983A cells
(Supplementary Fig. 1k, l) and this induced increased melano-
sphere formation, increased cell rounding and increased Myosin II
activity (Supplementary Fig. 1m–o).
Overall, these data show that amoeboid cells are more
tumourigenic and sustain self-renewal and tumour initiation in
melanoma.
EMT genes regulated by ROCK1/2 control amoeboid invasive
features. Melanoma is a non-epithelial tumour, hence acquisition
of invasive features is not considered a canonical EMT27. Never-
theless, EMT gene expression has been associated with the acqui-
sition of stem cell-like properties. ssGSEA analysis in our signature
for amoeboid melanoma cells10 revealed that amoeboid A375M2
cells were enriched in both EMT and metastasis-related gene sig-
natures (Fig. 2a). Of note, we also found that amoeboid cells
express genes from NC and invasive signatures associated with
drug resistance4,24 (Figs. 1a, 2a). The generated amoeboid tran-
scriptomes were obtained after 24 h of ROCK1/2-Myosin II
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inhibition10. To assess more direct effects of ROCK1/2 inhibition,
we performed an EMT-directed qPCR array in A375M2 and
WM1361 melanoma cells (BRAFV600E or NRASQ61L-driven mel-
anoma, respectively, to account for the main melanoma oncogenic
drivers) treated with ROCKi for only 4 h. At this time point, loss
of cell rounding and decreased Myosin II activity were already
observed (Fig. 2b). Interestingly, ROCKi decreased expression
of 72% and 59% of EMT-related genes in A375M2 and
WM1361 cells, respectively (Fig. 2c and Supplementary Fig. 2a).
ROCKi treatment resulted in significantly reduced expression of
key EMT regulators, such as SNAI family members and the
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(Fig. 2c). These data show that ROCK1/2 are positive regulators of
EMT-related gene expression, independently of melanoma onco-
genic background.
To identify key signalling pathways associated with this gene
signature, network enrichment analysis was performed. The most
significantly enriched network was centred on Wnt and TGFβ
signalling, while the second one encompassed NF-κB and
STAT3 signalling (Supplementary Fig. 2b, c). We selected genes
from these top networks with no prior link to amoeboid
migration (WNT11, WNT5B, AHNAK, TCF4 and CAV2) and
investigated if they could regulate amoeboid features. As positive
control, SERPINE1 was selected as a gene from our top network
previously described to support amoeboid behaviour28. Amoe-
boid cells are characterised by rounded morphology and high
Myosin II activity, so we first measured these two features on
WM1361 cells grown on collagen I matrices. Reducing expression
of SERPINE1, WNT11, WNT5B, AHNAK and TCF4 led to both
decreased cell rounding and decreased Myosin II activity
(Fig. 2d–f). During melanoma progression, melanoma cells
detach from the surrounding keratinocytes in order to invade
the dermis. Amoeboid melanoma cells adhere less to keratino-
cytes and migrate more efficiently through collagen I compared
with elongated cells with lower Myosin II7. We found that
SERPINE1, WNT11, WNT5B and CAV2 depletion increased
adhesion of WM1361 cells to keratinocytes (Fig. 2g), while
depletion of SERPINE1, WNT11, WNT5B and AHNAK reduced
3D invasion through collagen I matrices (Fig. 2h). In summary,
WNT11, WNT5B and SERPINE1 (our positive control) had an
impact in all assays (Fig. 2i). We next validated the role of non-
canonical Wnt ligands in regulating amoeboid features found in
our screens. Using three different RNAi to reduce WNT11
expression, we measured decreased cell rounding, Myosin II
activity and reduced invasion (Supplementary Fig. 2d–g) in both
A375M2 and WM1361 cells. Similar results were obtained after
WNT5B knockdown (Supplementary Fig. 2h–j).
These results show that non-canonical Wnt ligands support
melanoma amoeboid invasion independently of oncogenic
background.
Non-canonical Wnt ligands support melanosphere formation
and amoeboid behaviour. Non-canonical Wnt ligands are
regulated by ROCK1/2 and in return these ligands control
amoeboid features, generating a positive feedback loop (Fig. 2c–i).
ROCK1/2-Myosin II has multiple cellular functions including cell
proliferation, migration or invasion7,9–11,29–31, while EMT has
been associated with increased stem cell-like properties17. We
first explored whether ROCK1/2-Myosin II sustains in vitro
tumour initiation by blocking the entire transcriptional pro-
gramme using different ROCKi (H1152 and GSK269962A).
Expression of stem cell-related genes (Fig. 3a and Supplementary
Fig. 3a), cell rounding and p-MLC2 levels (Supplementary Fig. 3b,
c) were decreased after treatment. Interestingly, using several
amoeboid cell lines, one single treatment with ROCKi impaired
melanosphere formation (Fig. 3b and Supplementary Fig. 3d). Of
note, in vitro 2D cell viability was reduced after 7 days (Fig. 3c
and Supplementary Fig. 3e). Similar results were obtained
blocking Myosin II directly with blebbistatin (Fig. 3b, c). These
effects were further confirmed to be ROCK1/2-Myosin II
dependent, since specific silencing of both ROCK genes (ROCK1/
2) or both MLC2 genes (MYL9 and MYL12B) reduced melano-
sphere formation in A375M2 and WM1361 cells (Fig. 3d and
Supplementary Fig. 3f, g). 2D cell viability was decreased after
7 days (Fig. 3e), while no effects were measured after 3 days
(Fig. 3f). These data show that we can transiently reduce Myosin
II levels without affecting melanoma cell viability but Myosin II
long-term depletion compromises cell survival.
We, therefore, next explored whether ROCK1/2-Myosin II
sustains tumour initiation via regulation of Wnt ligands and
independently of other functions. Interestingly, reducing levels of
WNT11 and WNT5B resulted in reduced melanosphere forma-
tion (Fig. 3g, h), while in vitro 2D cell viability was unaffected
after 7 days (Fig. 3i, j). These data suggest that Wnt ligands
support both amoeboid features and specifically in vitro melano-
sphere formation. On the other hand, Wnt signals can be
produced by tumour cells as well as by stromal cells in the tumour
microenvironment32. Elongated A375P cells treated with either
WNT11 or WNT5B ligands increased cell rounding (Fig. 3k).
These results indicate that melanoma cells are capable of
regulating amoeboid features in response to non-canonical Wnt
ligands in an autocrine and paracrine manner.
FZD7 downstream of WNT11 supports melanosphere forma-
tion and amoeboid invasion via DAAM1. Non-canonical Wnt
ligands can signal through different Fzd receptors and co-
receptors. Using our microarray data for amoeboid melanoma
cells10, we found that most of the receptors for WNT11 and
WNT5B were overexpressed in amoeboid A375M2 cells (Fig. 4a).
Since amoeboid cell content is enriched in advanced stages
of melanoma progression7,8,10,12, we used publicly available
data33–35 to investigate receptor expression for non-canonical
Fig. 1 Amoeboid cells support tumour initiation in melanoma in vitro and in vivo. a Heatmap displaying enrichment scores for differentially expressed
stem cell-related signatures in amoeboid A375M2 cells compared to A375P cells or to A375M2 cells treated with ROCK1/2 inhibitors (ROCKi) (H1152 and
Y27632) or blebbistatin using single-sample Gene Set Enrichment Analysis (ssGSEA). b, c Limiting dilution assay estimating b tumour-initiating frequency
(TIF) and c tumour volume of A375M2 and A375P cells when injected at different dilutions (500,000, 50,000 and 5,000 cells) into NOD/SCID/
IL2Rγ−/− (NSG) mice (Number of tumours per condition indicated in table). TIF was determined using ELDA. d, e Representative images (left) and
quantification (right) of dmelanoma cell shape score and e H-score of p-MLC2 staining in tumour body (TB) and invasive front (IF) of A375M2 (n= 9) and
A375P (n= 8) tumours from 50,000 cells’ condition from (b). Scale bar, 100 μm; inset, 25 μm. f Representative phase-contrast images (top) and
quantification of sphere formation index (bottom) of A375P (n= 3) and WM983A cells (n= 4) serially passaged. Scale bar, 250 μm. g, h Representative
images (top) and quantification (bottom) of g H-score of p-MLC2 staining and h ki-67 positive cells in A375P and WM983A spheres serially passaged
(n= 4). Scale bar, 50 μm. i–k Representative i phase-contrast and j, k confocal images (top) and quantification (bottom) of i cell morphology (>250 cells
pooled from n= 3), j p-MLC2 immunofluorescence signal normalized by cell area (>80 cells pooled from n= 4) and k percentage of blebbing cells (5 fields
of view per experiment, >75 cells per experiment, n= 3) of individual A375P and WM983A cells from adherent conditions (P0) and from dissociated cells
from spheres serially passaged (P1–P3) on collagen I matrix. Scale bar, i, j 50 μm and k 20 μm. c–e, i, j Box limits show 25th and 75th percentiles, the
horizontal line shows the median, and whiskers show the minimum and maximum range of values. f–h, k Graphs show mean ± s.e.m. f–k n means number
of independent biological experiments. c two-tailed t-test. d–h, k One-way ANOVA with Tukey post-hoc test. i, j Kruskal–Wallis with Dunn’s multiple
comparison test. For all graphs, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. The exact significant p values for *p, **p and ***p are provided in
Supplementary Table 1. Mouse schematic in this figure was created using Servier Medical Art templates licensed under a Creative Commons Attribution
3.0 Unported License (https://smart.servier.com).
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Wnt ligands in primary and metastatic human melanomas
(Fig. 4b). In particular, WNT11-cognate receptor FZD7 and its
co-receptor RYK were both consistently upregulated in meta-
static melanomas in most of the studies. Importantly, FZD7
silencing resulted in the strongest reduction of melanosphere
formation (Fig. 4c), while depletion of either FZD7 or RYK did
not affect in vitro 2D cell viability (Fig. 4d). FZD7 silencing also
resulted in loss of cell rounding (Fig. 4e) and decreased Myosin II
activity (Fig. 4f and Supplementary Fig. 4a, b). Moreover, FZD7
depletion impaired invasion through 3D collagen I matrix
(Fig. 4g). FZD7 effects were further validated using two different
shRNAs (Supplementary Fig. 4c–g). These data suggest that
a
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FZD7 is an important regulator of amoeboid cell invasion and
melanosphere formation.
After binding to their cognate receptors, non-canonical Wnt
ligands can signal through two key molecular platforms: Dvl-
PLCB mediated calcium signalling36 and Dvl-DAAM1-Rho
signalling37,38. To establish specificity, we investigated the effects
of PLCB1 and DAAM1 depletion. PLCB1 was chosen among its
different isoforms as it is upregulated in melanoma metastasis
(Supplementary Fig. 4h). Either PLCB1 or DAAM1 silencing
decreased basal levels of cell rounding and p-MLC2 (Fig. 4h and
Supplementary Fig. 4i, j), indicating that both pathways are able
to control basal Myosin II activity. However, only DAAM1 but
not PCLB1 depletion impaired melanosphere formation in both
A375M2 and WM1361 cells (Fig. 4i) without affecting 2D cell
viability (Fig. 4j). In addition, DAAM1 silencing decreased
invasion through 3D collagen I matrix (Fig. 4k). DAAM1 effects
were further validated using two different shRNAs (Supplemen-
tary Fig. 4k–o). Moreover, expression of stem cell-related markers
was decreased in shDAAM1 cells (Supplementary Fig. 4p). These
results suggest an important role of DAAM1 controlling
amoeboid invasion and tumour-initiating potential.
We have shown that WNT11 can promote amoeboid features
in melanoma cells in a paracrine manner (Fig. 3k). Crucially, we
found that the increase in cell rounding measured after
WNT11 stimulation was no longer observed in DAAM1 depleted
cells, while PLCB1 depleted cells still responded to the ligand
(Fig. 4l and Supplementary Fig. 4q). Furthermore, WNT11 sti-
mulated RhoA activity and downstream Myosin II levels in
melanoma cells, but this effect was lost when DAAM1 was
silenced (Fig. 4m, n).
Altogether, these results show that WNT11/5B-FZD7-DAAM1
pathway control melanosphere formation and amoeboid invasive
behaviour by activation of a specific pool of RhoA-ROCK1/2-
Myosin II.
FZD7-DAAM1-RhoA-ROCK1/2 supports tumour initiation
and metastasis in vivo. We next tested whether the FZD7-
DAAM1-RhoA-ROCK1/2-Myosin II axis might affect melanoma
in vivo. First, A375M2 cells were pre-treated with different
ROCKi (H1152 and GSK269962A) ex vivo for 5 days. Relative
number of cells were reduced (Supplementary Fig. 5a). Never-
theless, only viable cells were subsequently injected sub-
cutaneously into immunodeficient NSG mice in equal numbers,
without any further treatment of animals. 18 days post-injection,
ROCKi pre-treated A375M2-derived tumours showed over 60%
reduction in tumour weight (Fig. 5a). Importantly, even if these
tumours had never received any treatment in vivo, we measured
reduced cell rounding, p-MLC2 levels and ki-67 positive cells in
ROCKi pre-treated tumours (Fig. 5b–d). Similarly, ROCKi pre-
treated B16F10 melanoma cells (Supplementary Fig. 5b, c)
injected subcutaneously into immunocompetent C57BL/6J mice
showed reduced tumour growth (Supplementary Fig. 5d) and
decreased amoeboid cell number in ROCKi pre-treated group
(Supplementary Fig. 5e–g). These results show that ROCK1/
2 supports the intrinsic abilities of both human and mouse
melanoma cells to form tumours by supporting amoeboid
features.
To examine the functional role FZD7 and DAAM1 might play
in tumour initiation in vivo, limiting dilutions of either shFZD7
or shDAAM1 WM1361 cells were injected subcutaneously into
NSG mice. Reduced FZD7 levels (Supplementary Fig. 5h) led to a
decrease in tumour growth when 50,000 and 5,000 cells were
injected, while no changes were observed with a saturating
concentration of 500,000 cells (Fig. 5e). Importantly, there was a
significant reduction in TIF using ELDA (Fig. 5e). An enrichment
in rounded cells (Fig. 5f) and p-MLC2 levels (Fig. 5g and
Supplementary 5i) was observed at the IF of shControl tumours
compared with TBs, while loss of cell rounding and reduced
Myosin II activity were measured in shFZD7 derived tumours
(Fig. 5f, g). shFZD7 tumours showed a decrease in cells with very
high Myosin II in the IF (Supplementary Fig. 5i). Although there
were no differences in cell numbers in vitro, shFZD7 tumours
in vivo displayed a reduction of the fraction of cells positive for
ki-67 proliferative marker (Fig. 5h). These data demonstrate that
FZD7 loss results in a reduction of the amoeboid proliferative cell
fraction in the tumour, leading to reduced tumour initiation.
We next assayed the in vivo tumour-initiating capacity of
limiting dilutions of shDAAM1WM1361 cells. DAAM1 depletion
(Supplementary Fig. 5j) yielded a reduction in TIF and a decrease
in tumour growth at limiting dilutions of 50,000 and 5,000 cells
(Fig. 5i). shDAAM1 tumours displayed pronounced loss of cell
rounding (Fig. 5j), Myosin II activity (Fig. 5k and Supplementary
Fig. 5k) and ki-67 positive cells (Fig. 5l). The in vivo tumour-
initiating capacity of DAAM1 in melanoma was further validated
using an additional melanoma cell line A375M2 (Supplementary
Fig. 5l–p). DAAM1 depletion led to a reduction in TIF and in
A375M2 tumour growth (Supplementary Fig. 5l). These results
confirm that FZD7-DAAM1-RhoA-ROCK1/2 promote tumour
initiation by sustaining melanoma amoeboid behaviour.
Cells at the IF of tumours are those strategically positioned to
leave the primary tumour and disseminate to distant sites. The
lung is one of the main sites to which melanoma metastasizes and
high Myosin II levels in amoeboid cells promote lung seeding and
Fig. 2 EMT genes regulated by ROCK1/2 control amoeboid invasive features. a Heatmap displaying enrichment scores for differentially expressed EMT
and metastasis-related signatures in amoeboid A375M2 cells compared to A375P cells or to A375M2 cells treated with ROCKi (H1152 and Y27632) or
blebbistatin using ssGSEA. b Representative phase-contrast images of A375M2 cells on top of collagen I matrix (left) and immunoblots of p-MLC2 in
A375M2 and WM1361 cells (right) after 4 h treatment with ROCKi (H1152) (n= 3). Scale bar, 50 μm. c Fold regulation of EMT-related gene expression
from EMT-directed qPCR array in A375M2 and WM1361 cells treated with ROCKi (H1152) for 4 h (n= 4). d Representative confocal images of p-MLC2
and F-actin staining in WM1361 cells on collagen I matrix after WNT11 knockdown (n= 3). Scale bar, 20 μm. e Quantification of cell morphology (>280
cells pooled from n= 3) and f p-MLC2 immunofluorescence signal normalized by cell area (>85 cells pooled from n= 3) in WM1361 cells on collagen I
matrix after depletion of indicated genes. g Representative confocal images (left) and quantification (right) of adhesion of WM1361 cells to a monolayer of
keratinocytes after depletion of indicated genes (n= 5 for SERPINE1, n= 4 for TCF4, n= 3 for WNT11, WNT5B, AHNAK and CAV2). Scale bar, 20 μm.
h Representative confocal images (left) and quantification (right) of 3D invasion index through a collagen I matrix of WM1361 cells after depletion of
indicated genes (n= 3). Scale bar, 50 μm. i Summary table of amoeboid functional assays on WM1361 cells after SERPINE1, WNT11, WNT5B, AHNAK, TCF4
and CAV2 knockdown. “+” sign indicates a significant phenotype of the corresponding gene knockdown. c, g, h Graphs show mean ± s.e.m. e, f Box limits
show 25th and 75th percentiles, the horizontal line shows the median, and whiskers show minimum and maximum range of values. b–h nmeans number of
independent biological experiments. c Two-tailed t-test with Benjamini, Krieger and Yekutieli correction for multiple comparisons. e, f Kruskal–Wallis
test with Benjamini, Krieger and Yekutieli correction. g, h One-way ANOVA with Benjamini, Krieger and Yekutieli correction. For all graphs, *p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001. The exact significant p values for *p, **p and ***p are provided in Supplementary Table 1.
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colonization7,12,14. To test the role of DAAM1 in both processes,
we used an experimental metastasis model. Similar cell numbers
lodged in the lung vasculature 30 min post-tail vein injection
(Supplementary Fig. 5q). However, shDAAM1 melanoma cells
were less efficient in colonising the lung after 24 h (Fig. 5m).
Strikingly, the area of metastatic lesions 3 weeks after was reduced
when DAAM1 was depleted (Fig. 5m). These results indicate that
DAAM1 is important for early stages of lung colonization and for
the ability to outgrow at later stages. Our data further suggest that
loss of amoeboid features has an impact both in early lung
seeding and later in metastatic outgrowth.
Amoeboid behaviour enhances tumour formation, tumour
progression and metastasis in vivo. We have shown that the
ROCK1/2-Myosin II amoeboid phenotype sustained by FZD7-
DAAM1 signalling supports tumour formation and dissemination.
ROCKi or
Blebbistatin
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Using an orthotopic spontaneous melanoma metastasis model, we
next recapitulated the steps of melanoma progression. Injection of
4599-BRAFV600E melanoma cells into the dermis of NSG mice
resulted in the formation of orthotopic tumours. Mice were then
systemically treated with ROCKi (Fig. 6a) since to our knowledge
no drugs were available for the effective/specific inhibition of non-
canonical FZD7-DAAM1 signalling in vivo. We observed three
defined areas in control tumours: TB, IF and a further area of local
invasion into the dermis (invading cells or distal invasive front
(DIF)) (Fig. 6b) closely recapitulating the human disease39. All
invading cells at the DIF displayed rounded-amoeboid features:
56% of them exhibited the highest Myosin II activity and 60.4% of
invading cells were positive for the proliferative marker ki-67
(Fig. 6c). Specifically, co-staining of p-MLC2 score 3 and ki-67 was
found in 30.2% of invading cells at the DIFs (Fig. 6c). These data
suggest that amoeboid invading cells are also proliferative.
Cell rounding (Fig. 6d), overall Myosin II activity (Fig. 6e) and ki-
67 positive cells (Fig. 6f) were progressively increased from TB
to IF to DIF in control tumours. Cells with very high Myosin II
were abundant in the IF and further enriched in the DIF (Fig. 6e
and Supplementary Fig. 6a, b). Importantly, ROCKi led to loss
of cell rounding and decreased Myosin II activity at IFs and
DIFs (Fig. 6d, e), while a reduction of ki-67 positive cells was
observed in all areas of ROCKi treated tumours (Fig. 6f). These
data suggest that ROCKi impairs amoeboid features and pro-
liferation in vivo.
Phenotype switching from proliferative to invasive states has
been implicated in melanoma progression18–20. However, our
transcriptional analysis showed that amoeboid A375M2 cells were
enriched in both proliferative and invasive genes (Fig. 6g and
Supplementary Fig. 6c, d). Moreover, enrichment in Myosin II
activity and ki-67 positive cells was found in IFs of A375M2
tumours (Fig. 1e and Supplementary Fig. 1a, c), suggesting that
the amoeboid phenotype sustained by ROCK1/2-Myosin II could,
in principle, support tumour formation and tumour dissemina-
tion. Remarkably, in accordance with its role in regulating both
proliferative and invasive genes, ROCKi caused a reduction in
primary tumour growth in 4599 tumours (Fig. 6h) and resulted in
loss of melanoma cells leaving the primary tumour and invading
into adjacent tissue (Fig. 6i, j). In line with reduced local invasion,
spontaneous lung metastasis was reduced dramatically in ROCKi
treated mice (Fig. 6k). Our results suggest that ROCK1/2-Myosin
II activity in amoeboid melanoma cells controls both tumour
growth and spread.
In the previous experimental setting, as both primary tumour
growth and local invasion were reduced, it was difficult to
separate these effects from those on metastasis. We next evaluated
the impact of ROCKi in melanoma metastatic colonisation and
outgrowth using tail vein injection assays. 4599 cells were pre-
treated with ROCKi for 24 h prior to intravenous injection and
continued treatment in vivo for 6 days. Cell survival in the blood
stream was not altered as similar cell numbers lodged in the lungs
30 min post-tail vein injection (Supplementary Fig. 6e). However,
ROCKi reduced lung metastatic establishment (Fig. 6l). Reduced
lung metastasis was also measured when 4599 cells -without any
pre-treatment- were intravenously injected, while 4 h after
injection mice received ROCKi systemic treatment for 12 days
(Fig. 6m).
Our data confirm that ROCK1/2-Myosin II activity is not only
important for tumour formation and invasion but also for early
colonization and later metastatic growth. This suggests that
ROCK1/2-Myosin II activity plays a crucial role in all steps of
melanoma progression.
Analysis of the invasive front of human primary melanomas.
To understand if amoeboid cells in the IF have increased
tumour-initiating features in the human clinical setting, we
analysed matched TBs and IFs of 53 human primary melanomas
(Supplementary Table 2). Cell morphology and p-MLC2 levels
were assessed as amoeboid markers; ki-67 staining as a pro-
liferative marker; WNT11, WNT5B and DAAM1 expression as
non-canonical Wnt markers; and ALDH1A1, ALDH1A3, CD44,
NANOG and OCT4 were evaluated as cancer stem cell-related
markers. In accordance with previous assessments in melanoma
patients7,10,12,15, we could measure that IFs of human melano-
mas were enriched in rounded-amoeboid cells with high Myosin
II activity (Fig. 7a, b and Supplementary Fig. 7a). Importantly, as
observed in our tumour models (Figs. 1, 5, 6), cells with very
high Myosin II were predominant at human IFs. Moreover, an
increase in the percentage of ki-67 positive cells was also found at
IFs (Fig. 7c). Interestingly, cells with higher levels of DAAM1,
WNT11 and WNT5B were also enriched in the IFs (Fig. 7d–f).
Cells with score 3 level of DAAM1 were predominant in these
areas (Supplementary Fig. 7b). Importantly, we found an
enrichment in ALDH1A1, CD44 and NANOG expression at
these IFs (Fig. 7g–i), while ALDH1A3 and OCT4 did not change
(Supplementary Fig. 7c, d). We provided regional information
showing high expression of amoeboid/non-canonical Wnt/stem
cell markers in the IF area of human primary tumours (Sup-
plementary Fig. 7e). Interestingly, principal component analysis
of all differentially expressed markers clearly separated TB and IF
areas in primary melanomas (Fig. 7j). Amongst all markers
investigated, ALDH1A1 enrichment was highest, showing a
median 13-fold increase in IFs. Strikingly, high ALDH1A1 pro-
tein expression in the IF appeared to confer worse prognosis and
shorter disease-free survival in our cohort of melanoma patients
(Fig. 7k, l). ALDH1A1 is a functional marker involved in self-
renewal and proliferation with key anti-oxidative roles40. Inva-
sive melanoma cells with high Myosin II harbour lower levels of
reactive oxygen species (ROS)8,24, while antioxidants promote
Fig. 3 Non-canonical Wnt ligands support melanosphere formation and amoeboid behaviour. a mRNA expression of stem cell-related markers by qRT-
PCR in A375M2 cells treated with ROCKi (GSK269962A) for 24 h compared to control A375M2 cells (n= 4 for ALCAM, ALDH1A3, ALDH1A1; n= 3 for
CD44, OCT4, JARID1B, SOX2). b Schematic of treatment (top), representative phase-contrast images (bottom left) and quantification of sphere formation
index (bottom right) and c cell viability of A375M2 cells and A375M2 cells treated with one dose of ROCKi (H1152 or GSK269962A) or blebbistatin (n=
3). Scale bar, 250 μm. d–f After ROCK1/2,MYL9 orMYL12B knockdown in A375M2 andWM1361 cells, quantification of d sphere formation index (n= 4 for
A375M2, n= 3 for WM1361) and e, f cell viability after e 7 days (n= 3 for A375M2, n= 4 for WM1361) or f 3 days (n= 3) of cell seeding. g–j AfterWNT11
or WNT5B knockdown in A375M2 and WM1361 cells, g, h representative phase-contrast images (left) and quantification of sphere formation index (right)
(n= 3) and i, j cell viability (n= 4 for A375M2, n= 3 for WM1361). Scale bar, 250 μm. k Representative phase-contrast images (left) and quantification of
cell morphology (right) of A375P cells after 24 h of WNT11 or WNT5B stimulation (>225 cells pooled from n= 3). Scale bar, 100 μm. a–j Graphs show
mean ± s.e.m. k Box limits show 25th and 75th percentiles, the horizontal line shows the median, and whiskers show minimum and maximum range of
values. a–k n means number of independent biological experiments. a–c, h, j Two-tailed t-test. d–g, i One-way ANOVA with Dunnett post-hoc test.
k Kruskal–Wallis with Dunn’s multiple comparison test. For all graphs, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. The exact significant p values for
*p, **p and ***p are provided in Supplementary Table 1.
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melanoma invasion and metastasis41,42. Moreover, higher ROS
levels reduce Myosin II activity8. Silencing ALDH1A1 led to
decreased melanosphere formation (Supplementary Fig. 7f, g).
Interestingly, ALDH1A1 depletion resulted in loss of cell
rounding and lower p-MLC2 levels (Supplementary Fig. 7h, i),
while ROS levels, as measured by FACS, were increased
(Supplementary Fig. 7j, k). Our data suggest that ALDH1A1-
supports amoeboid tumour-initiating features via regulation of
ROS metabolism. Overall, these data illustrate that the IFs of
human primary melanomas are tumour areas enriched in
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Analysis of the invasive front of human metastatic melanomas.
To further investigate if melanoma cells retain this phenotype
during the course of secondary tumour formation, 45 matched
TBs and IFs from human melanoma metastases were assessed
(Supplementary Table 3). Metastatic melanomas retained the
same regional distribution identified in primary tumours; that is,
amoeboid (Fig. 8a, b and Supplementary Fig. 8a) and pro-
liferative cells (Fig. 8c) were prominent in the IF areas, and that
IFs also had an enrichment in non-canonical Wnt markers
(Fig. 8d–f and Supplementary Fig. 8b) and stem cell-related
markers (Fig. 8g–i and Supplementary Fig. 8c, d). Importantly,
the overall levels of all markers were higher in metastasis. In fact,
TBs from metastatic lesions were more amoeboid, more pro-
liferative and had a higher basal level of some non-canonical
Wnt and stem cell-related markers (Supplementary Fig. 8e–h)
when compared to primary tumour TBs. As a result, the
increased expression of all markers in metastatic IFs was not as
pronounced as in the primary tumour setting. These results show
that the amoeboid tumour-initiating phenotype found in pri-
mary IFs is recapitulated and further enhanced in metastatic
melanoma specimens. Overall, our data show that amoeboid cell
invasive/proliferative behaviour is selected during melanoma
progression.
Discussion
Melanoma is a highly aggressive tumour that is able to metastasize
from very early stages of the disease. The high migratory ability of
melanoma cells has been explained in part by its NC origin1.
Signalling pathways involved in NC development and melanoma
progression are closely related2,3. Here, we provide evidence that
amoeboid melanoma cells display increased tumour-initiating
abilities. We show that rounded-amoeboid cells with high Myosin
II activity and high levels of ki-67 are associated with increased
tumour initiation capacity in vitro and in vivo. ROCK1/2-Myosin
II pathway is a key regulator of cell proliferation, migration,
invasion and metastatic behaviour7,9–11,29–31. We have recently
reported that Myosin II activity drives therapy resistance in
melanoma24, a mechanism closely related with tumour-initiating
cell properties25,43. NC stem cell transcriptional states play a
critical role in driving relapse and drug resistance in melanoma4.
Moreover, analysis of our transcriptional signature for amoeboid
melanoma cells10 reveals that amoeboid cells are enriched in NC
and invasive signatures associated with drug resistance4,24. On the
other hand, tumour-initiating cells are supposed to represent a
small cell population in a slow proliferative state25. However, it
has been described that they can proliferate vigorously and
tumour-initiating cell frequencies up to 25% have been
reported6,44,45. Ki-67 can affect clonogenic stem cell properties46,
and sub-populations of ki-67 proliferating stem cells have also
been found in some tumours26.
Importantly, we also find that amoeboid melanoma cells
express EMT-related genes driven by ROCK1/2. Rho-ROCK1/
2 signalling has been shown in other models to regulate actin
cytoskeleton rearrangements during EMT47 while promoting
transcriptional changes through activating p38 signalling48,49.
Interestingly, ROCK1/2 regulates TGFβ expression in our EMT
array and TGFβ signalling is one of the top networks associated
with the EMT gene signature regulated by ROCK1/2. We have
also shown that amoeboid cells secrete high levels of TGFβ and its
secretion is ROCK1/2 dependent7,15,24. TGFβ is a key driver of
EMT by inducing transcription of several mesenchymal genes
and increasing the activity of EMT transcription factors47,50. This
suggests TGFβ as one of the possible mechanisms by which
ROCKs modulate a global EMT gene program and, on the other
hand, amoeboid invasion7.
Among these EMT-related genes regulated by ROCKs, we find
Wnt ligands. Such genes, in turn, drive amoeboid features. Spe-
cifically, we find that the WNT11/5B-FZD7-DAAM1 signalling
axis has an impact on tumour initiation by controlling the
amoeboid phenotype. WNT11-DAAM1 signalling has been
described to play an essential role in NC migration51–53, NC
formation and NC specification during early embryonic
development54,55. WNT5A through Ca2+ and PKC signalling has
been described to play a role in melanoma progression56, while
other Wnt ligands have not been studied in detail. We show that
WNT11 and WNT5B control amoeboid self-renewal and invasive
behaviour. Moreover, melanoma cells could exploit paracrine
Wnt signalling from stroma32, sustaining the amoeboid pheno-
type, as long as they express the correct receptor repertoire. We
find that FZD7 receptor downstream of WNT11/WNT5B ligands
is upregulated during melanoma progression and we show this
receptor sustains amoeboid behaviour. Limiting-dilution analysis
revealed how FZD7 supports in vivo tumour-initiating abilities
and tumour growth in melanoma, consistent with previous
reports in other tumours57. Importantly, our work has unravelled
a crucial role for DAAM1 in promoting both tumour and
metastasis initiation and later metastatic outgrowth in melanoma
by regulating amoeboid features. DAAM1 is a formin-homology
protein that plays a central role in translating signals from Wnt
ligands to the actin cytoskeleton37. Unlike other formins,
DAAM1 activation is specifically mediated by its binding with
Dvl upon Wnt stimulation rather than by its interaction with
Fig. 4 FZD7 downstream of WNT11 supports melanosphere formation and amoeboid invasion via DAAM1. a, b Heatmap representing log2 fold change
in expression of non-canonical Wnt receptors in a A375M2 cells compared to A375P cells or A375M2 cells treated with ROCKi (H1152 and Y27632) and
blebbistatin and in b metastatic versus primary melanoma samples from indicated studies from GEO and TCGA databases. c–f After FZD7 or RYK
knockdown in A375M2 and WM1361 cells, quantification of c sphere formation index (n= 4 for A375M2, n= 3 for WM1361), d cell viability (n= 5 for
A375M2, n= 3 for WM1361), e cell morphology (>300 cells pooled from n= 3) and f p-MLC2 levels (n= 3 for A375M2, n= 4 for WM1361). g
Quantification of 3D invasion index through a collagen I matrix after FZD7 knockdown in A375M2 (n= 5) and WM1361 cells (n= 3). h–j After PLCB1 or
DAAM1 knockdown in A375M2 and WM1361 cells, quantification of h cell morphology (>250 cells pooled from n= 3), i sphere formation index (n= 4)
and j cell viability (n= 6 for A375M2, n= 3 for WM1361). k Quantification of 3D invasion index through a collagen I matrix after DAAM1 knockdown in
A375M2 (n= 4) and WM1361 cells (n= 3). l Representative phase-contrast images (left) and quantification of cell morphology (right) of A375P cells on
collagen I matrix after WNT11 stimulation and PLCB1 or DAAM1 knockdown (>400 cells pooled from n= 5). Scale bar, 100 μm. m, n Representative
immunoblots (top) and quantification (bottom) of m RhoA-GTP in pulldown samples and total RhoA in total lysate (n= 3) and n p-MLC2 levels (n= 4) in
A375P cells after WNT11 stimulation and DAAM1 knockdown. c, d, f, g, i–k, m, n Graphs show mean ± s.e.m. e, h, l Box limits show 25th and 75th
percentiles, the horizontal line shows the median, and whiskers show minimum and maximum range of values. c–n n means number of independent
biological experiments. a, g, k Two-tailed t-test. b Two-tailed t-test with Welch’s correction. c, d, f, i, j One-way ANOVA with Dunnett post-hoc test. e, h
Kruskal–Wallis with Dunn’s multiple comparison test. l Kruskal–Wallis test with Benjamini, Krieger and Yekutieli correction. m, n One-way ANOVA with
Tukey post-hoc test. For all graphs, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. The exact significant p values for *p, **p and ***p are provided in
Supplementary Table 1.
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active Rho GTPases37,38. Such mechanisms have been described
during development, but not during cancer initiation or pro-
gression. Therefore, we highlight here yet another example of
cancer cells hijacking a developmental program. On the other
hand, DAAM1 promotes RhoA activation37,38 via recruitment of
PDZ-RhoGEF58. In accordance, using the Human Protein Atlas,
we find that this PDZ-RhoGEF is highly expressed in melanoma
compared to other cancers (Supplementary Fig. 8i). We propose
here that non-canonical WNT11/5B-FZD7-DAAM1 axis cru-
cially and specifically controls tumour initiation potential in
melanoma by promoting ROCK1/2-Myosin II driven amoeboid
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Furthermore, we provide evidence that amoeboid cells are
selected during several steps of melanoma progression. In the
current study, we use potent and selective ROCKi to demonstrate
that ROCK1/2-Myosin II axis is an important regulator of tumour
growth and metastasis in melanoma. We have reported that
amoeboid melanoma cells support tumour growth by reprogram-
ming the immune microenvironment15. Furthermore, the tumour
microenvironment can regulate ROCK2-Myosin II to support
tumour growth59. We demonstrate here that in melanoma
ROCK1/2-Myosin II also plays an important pro-tumourigenic
role via cell autonomous mechanisms. Importantly, amoeboid
melanoma cells express genes from both proliferative and invasive
signatures18,19. We show the in vivo existence of amoeboid
invading cells that are positive for the ki-67 proliferative marker
and harbour very high levels of Myosin II. Such a population is also
impaired when blocking the whole pathway with ROCKi. In a
recent study, a subpopulation of melanoma cells has been identi-
fied that simultaneously displays proliferative and invasive prop-
erties as a result of high transcriptional TGFβ signalling
activation60. Since their gene ontology analysis show an enrich-
ment in amoeboid features60, it is tempting to speculate that this is
the same population of melanoma cells.
In this study, we demonstrate that the amoeboid proliferative
and invasive phenotype promoted by non-canonical WNT-
DAAM1 signalling is required for tumour initiation in melanoma
and for both initial and late metastatic stages. We suggest that
amoeboid melanoma cells sustain the expression of an EMT and
stem cell-related gene signature to successfully metastasize. In
agreement with this concept, assessment of patient biopsies
revealed that IFs of human primary melanomas are enriched in
amoeboid, proliferative, non-canonical Wnt and cancer stem cell-
related markers. Functional stem cells that drive tumour expansion
and proliferative cells have been described to reside at the tumour
edge of some tumours61. Moreover, ki-67 index and mitotic rate
are indicative of neoplastic progression and appear as prognostic
factors in melanoma23,62,63. Furthermore, within this amoeboid
tumour-initiating phenotype, we identify ALDH1A1, a key gene
for tumour-initiating abilities. Importantly, loss of ALDH1A1
results in loss of the amoeboid phenotype and vice versa. Since
ALDH1A1 has been implicated in tumour-initiating capacity in
melanoma and has been associated with drug resistance64,65, we
propose ALDH1A1 as a potential prognostic marker in melanoma
patients. Importantly, we find metastatic melanoma lesions to
recapitulate the behaviour of primary tumours and show an
enhancement of the amoeboid tumour-initiating pattern.
Overall, we have unveiled how WNT11B/5B-FZD7-DAAM1 in
amoeboid cells supports tumour-initiating properties, while also
promoting invasion. Since amoeboid cells are prominent at the
edge of tumours, our work sheds some light into the early ability
of melanomas to disseminate and grow at distant sites. We pro-
pose that the IFs of melanoma tumours are areas with important
prognostic features that pathologists should carefully evaluate.
Furthermore, after surgical melanoma removal, we suggest inhi-
biting non-canonical Wnt signalling to eradicate aggressive
amoeboid behaviour at the edge of tumours.
Methods
Cell culture. Cells were grown at 37 °C and 10% CO2 in DMEM (A375M2, A375P,
B16F10, 4599, HEK293T and HaCaT) or RPMI (WM1361, WM983B and
WM983A) supplemented with 10% FBS and 1% penicillin/streptomycin (all from
Gibco). A375M2 and A375P cells were from Prof. Richard Hynes (HHMI, MIT,
USA), WM1361 cells were from Prof. Richard Marais (Cancer Research UK
Manchester Institute, UK), WM983B and WM983A were purchased from Coriell
Institute, B16F10 cells were from Dr. Hector Peinado (CNIO, Spain), 4599 cells
were from Dr. Amine Sadok (Institute of Cancer Research, UK) and Prof. Richard
Marais, HEK293T cells were from Dr. Jeremy Carlton (The Francis Crick Institute,
UK), and HaCaT cells were from Dr. Ester Martin-Villar (IIBM, UAM, Spain).
A375M2, A375P, WM983B, WM983A and 4599 were authenticated using short
tandem repeat DNA profiling. All cell lines were routinely tested for mycoplasma
contamination. All cell lines were kept in culture for a maximum of three to four
passages and cell phenotypes were verified routinely.
Sphere formation assay. The sphere-forming assay was performed as previously
described66. Briefly, individual cells were plated in 100 µl of Sphere Media
(DMEM/F12 supplemented with 1:50 B27 (Invitrogen), 20 ng/ml EGF (PHG0315,
Invitrogen), 20 ng/ml FGF (PHG0026, Invitrogen), 4 mg/ml heparin (H3149,
Sigma) and 1% penicillin/streptomycin) in ultra-low-attachment 96-well plates
(Costar) at a density of 1,000 cells/well and kept at 37 °C and 10% CO2. For serial
passages, melanospheres were collected by centrifugation followed by enzymatic
(trypsin treatment for 10 min at 37 °C) and mechanical dissociation using 25G
needles. The resulting single-cell suspension was counted and re-plated at the
original density. In all assays, melanosphere formation was quantified after 7 days.
The Sphere Formation Index (SFI) considered both, number and size of the
spheres, and was calculated by summing the area of all spheres formed, divided by
the number of single cells initially plated. In each biological experiment, 2–3
technical replicates were performed and average SFI considered. Quantitative
analysis of images was performed using ImageJ.
Cell culture on thick layers of collagen I. Bovine collagen I (no. 5005-B; PureCol,
Advanced BioMatrix) thick layer was prepared at 1.7 mg/ml as previously
described10,12. After polymerization (4 h), cells were seeded on top of collagen in
medium containing 10% FBS, allowed to adhere for 16 h and media was changed to
1% FBS with corresponding treatments (where appropriate). Cells were analysed
24 h later. At the end of the experiment, gels were fixed with 4% formaldehyde and
imaged or lysates were collected.
Fig. 5 FZD7-DAAM1-RhoA-ROCK1/2 supports tumour initiation and metastasis in vivo. a Schematic of experiment (left) and tumour weight (right) of
ROCKi (H1152 or GSK269962A) pre-treated A375M2 cells 18 days post-subcutaneous injection into NSG mice (n= 5 mice for control and H1152, n= 4 for
GSK269962A). b–d Quantification of b melanoma cell shape score, c H-score of p-MLC2 staining and d ki-67 positive cells in A375M2 tumours from (a).
e Limiting dilution assay estimating TIF (top) and tumour volume (bottom) of shControl and shFZD7 WM1361 cells when injected at different
dilutions (500,000, 50,000 and 5,000 cells) into NSG mice (Number of tumours per condition indicated in table). TIF was determined using ELDA.
f–h Representative images (top) and quantification (bottom) of f melanoma cell shape score, g H-score of p-MLC2 staining and h ki-67 positive cells in TB
and IF of shControl (n= 16) and shFZD7 (n= 9) derived tumours from 50,000 cells’ condition from (e). Scale bar, 100 μm; inset, 25 μm. i Limiting dilution
assay estimating TIF (top) and tumour volume (bottom) of shControl and shDAAM1 WM1361 cells when injected at different dilutions (500,000, 50,000
and 5,000 cells) into NSG mice (Number of tumours per condition indicated in table). TIF was determined using ELDA. j–l Representative images (top) and
quantification (bottom) of j melanoma cell shape score, k H-score of p-MLC2 staining and l ki-67 positive cells in TB and IF of shControl (n= 10) and
shDAAM1 (n= 5) derived tumours from 50,000 cells’ condition from (i). Scale bar, 100 μm; inset, 25 μm. m Representative confocal images (left) and
percentage of fluorescence area (right) of mouse lungs 24 h (n= 6 mice) and 3 weeks (n= 5 mice) after tail vein injection into NSG mice of WM1361 cells
expressing shControl and shDAAM1. Scale bar, 50 μm. a, m Graphs show mean ± s.e.m. b–l Box limits show 25th and 75th percentiles, the horizontal line
shows the median, and whiskers show minimum and maximum range of values. a–d One-way ANOVA with Dunnett post-hoc test. e, i Two-tailed
Mann–Whitney test. f–h, j–l One-way ANOVA with Tukey post-hoc test. m Two-tailed t-test. For all graphs, *p < 0.05, **p < 0.01, ***p < 0.001, ****p <
0.0001. The exact significant p values for *p, **p and ***p are provided in Supplementary Table 1. Schematics in this figure were created using Servier
Medical Art templates licensed under a Creative Commons Attribution 3.0 Unported License (https://smart.servier.com).
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Analysis of cell morphology. Cell morphology was quantified on phase-contrast
images of cells cultured on top of bovine collagen I matrices using ImageJ as
previously described12,15,24. Cell morphology was assessed using the morphology
descriptor tool “roundness” after manually drawing around the cell shape.
Roundness index is calculated as 4 × area/π ×major_axis_length2. Values closer to
1 represent rounded morphology; values closer to 0 represent more spread and/or
spindle-shaped cells.
Drug treatments. Contractility inhibitors and concentrations used in this study
were: 5 μM H1152 (stock resuspended in water; #555550, Calbiochem), 1 µM or 5
µM GSK269962A (stock resuspended in DMSO; #1167, Axon) and 25 µM bleb-
bistatin (stock resuspended in 95% DMSO; #203390, Calbiochem). Time of
treatment was as specified in each experiment. WNT11 (200 ng/ml; 6179-WN-010,
R&D Systems,) and WNT5B (500 ng/ml; 7347-WN-025, R&D Systems) were
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Transfection and RNAi. 2 × 105 cells/well were seeded on 6-well plates and
transfected the next day with 20 nM siGenome SmartPool (SP) or On-Targetplus
(OT) siRNA oligonucleotides, using Optimem-I and Lipofectamine 2000 (Invi-
trogen). For sphere formation assays and cell viability assays, cells were re-
transfected after 24 h. In all assays, 48 h after transfection, cells were harvested and
equal numbers were re-seeded for subsequent analyses. All siRNA sequences were
from Dharmacon (Lafayette, USA) and are listed in Supplementary Table 4. In all
siRNA experiments, Non-Targeting siRNA was used as control.
Lentivirus generation and infection of melanoma cells. 4 × 105 HEK293T cells
on 6-well plates were transfected with lentiviral vector (1 μg) along with packaging
vectors (p-MD2.VSVg (0.4 μg) and pΔ8.91 (1 μg)) using Optimem-I and Lipo-
fectamine 2000 (Invitrogen). Supernatants with lentiviruses were collected 48 h
after transfection, spun down and filtered (0.45 μm). For lentiviral transduction,
2 × 105 melanoma cells/well were seeded in 6-well plates and infected with lenti-
viruses. Stable cells were selected with 1 μg/ml puromycin (Life Technologies).
FZD7 and DAAM1 silencing was achieved using pGIPZ Lentiviral shRNA con-
structs expressing TurboGFP from Dharmacon (Lafayette, USA): shFZD7 #1
(V3LHS_368263 5′-AGAGCACGCTGAAGACGCC-3′), shFZD7 #2
(V3LHS_368264 5′-CGTGTTTCATGATGGTGCG-3′), shDAAM1 #1
(V3LHS_339679 5′-TTGTGATTGGTCTCTCTCT-3′), shDAAM1 #2
(V3LHS_339678 5′-TTAGATTGAGAACACTGGG-3′), Non-silencing shControl
(5′-ATCTCGCTTGGGCGAGAGTAAG-3′). EGFP-fused rat wild-type MCL2
plasmid was obtained from Dr. Tohru Takaki and Prof Erik Sahai67.
Immunoblotting and antibodies. Cells were lysed in Laemmli sample buffer,
boiled for 5 min, sonicated for 15 s and spun down. Lysates were fractionated using
10% or 12% SDS-polyacrylamide gel electrophoresis and transferred onto PVDF
filters (0.45 µm, Immobilon). ECL or Prime ECL detection Systems (GE Health-
care) with HRP-conjugated secondary antibodies (GE Healthcare) were used for
detection. Bands were quantified using Image J. Levels of phospho-proteins were
calculated after correction to total levels of the relevant protein. Antibodies:
pThr18/Ser19-MLC2 (1:750, #3674), MLC2 (1:750, #3672) and RhoA (1:1000,
#2117) from Cell Signalling Technology; GFP (1:10000, sc-8334) from Santa Cruz
Biotechnology; GAPDH (1:10000, MAB374) from Millipore.
RhoA-GTP pulldown assay. RhoA-GTP pulldown assays were performed as
described8,14. 2 × 105 cells/well were seeded on 6-well plates, serum starved and
treated with WNT11 as indicated above. Cells were lysed in lysis buffer containing
50 mM Tris pH 7.4, 10% glycerol, 1% NP40, 5 mM MgCl2, 100 mM NaCl, 1 mM
DTT and EDTA free protease inhibitor and spun down. A small proportion of
protein lysates were separated for determination of total RhoA levels. The
remaining protein lysate was incubated with glutathione S-transferase (GST)-
conjugated with Rhotekin RBD beads for 1 h. Beads were collected by cen-
trifugation, washed and resuspended in loading buffer. All samples were boiled for
5 min and resolved by SDS-polyacrylamide gel electrophoresis. RhoA was detected
by immunoblot.
Confocal fluorescence microscopy and image quantification. Cells were seeded
on top of a collagen I matrix and immunostained as described12. Cells were fixed
with 4% formaldehyde, permeabilised with 0.3% Triton X-100, blocked with 5%
bovine serum albumin (BSA), and stained with primary antibody pSer19-MLC2
(1:200, #3671, Cell Signalling), which was detected with secondary Alexa Fluor 488
or 647 antibodies (Life Technologies). F-actin was stained using Alexa Fluor 546-
phalloidin (Life Technologies) and nuclei with Hoechst 33258 (Life Technologies).
Antibodies were diluted in 5% BSA-PBS. Imaging was carried out on Zeiss LSM
510 Meta confocal microscope with Plan-Apochromat 40x/1.2 NA (water) objec-
tive lenses and Zeiss LSM 710 confocal microscope with Plan-Apochromat 40x/1.3
Oil or a Plan-Apochromat 63x/1.4 NA (oil) objective lenses (Carl Zeiss) and Zen
software. Images were analysed using ImageJ. p-MLC2 fluorescence signal was
quantified calculating the pixel intensity in single cells relative to the cell area.
Adhesion assays to keratinocyte monolayer. HaCaT keratinocytes were seeded
in a 96-well plate at 105 cells/well and, 24 h later, melanoma cells stained with
CMFDA green dye (10 µM, Life Technologies) were seeded on top at 104 cells/well.
After 2 h at 37 °C, cells were imaged. Plates were then washed twice with PBS and
re-imaged. Percentage of adhering cells was calculated as the number of cells
imaged after vs before washing.
3D invasion assays. Cells were suspended in serum-free bovine collagen I at 2.3
mg/ml to a final concentration of 1 × 104 cells per 100 μl of matrix, seeded on 96-
well plates and spun down to the bottom of the well. After matrix polymerization,
10% FBS-containing media was added on top of the matrix, allowing the cells to
invade upwards for 24 h as previously described8,14. Then, plates were fixed in 4%
formaldehyde, stained with 5 µg/ml Hoechst 33258 (Life Technologies) and imaged
on Zeiss LSM 510 or Zeiss LSM 710 confocal microscopes (Carl Zeiss) with Zen
software. Confocal z-slices were collected from each well at the bottom of the well
and at 50 µm. The 3D invasion index was calculated as number of invading cells at
50 µm divided by the total number of cells.
Intracellular measurement of ROS. Cells were harvested and incubated with 5
μM CellROX Green Reagent (Life Technologies) at 37 °C for 30 min in the dark.
Then, cells were diluted with FACS buffer (PBS−, 1% BSA, 2 mM EDTA, 0.1%
NaN3) and fluorescence was analysed by flow cytometry using a BD LSRFortessa™
system (Flow Cytometry Core, Barts Cancer Institute) and FlowJo software
(Supplementary Fig. 7k). Cells were first gated on FSC-A vs SSC-A to eliminate cell
debris. Then, discrimination of doublets was performed on FSC-A vs FSC-H and
SSC-A vs SSC-W. Only viable and single cells were used for the analysis. CellROX
green positivity was analysed using mean fluorescence intensity.
Cell viability assay. Cells stably expressing shRNAs or cells after 48 h transfection
with siRNAs were seeded in 6-well plates (25,000 cells/well). For ROCKi experi-
ments, 25,000 cells were seeded in 6-well plates, allowed to adhere and treatment
was performed as indicated for each experiment. Cell viability was assessed after
7 days in all experiments, while for MYL9 and MYL12B siRNA experiments that it
was assessed after 3 and 7 days. Then, cells were fixed with 1% formaldehyde and
stained with 0.25% crystal violet. After air-drying, crystal violet stain was dissolved
in 10% acetic acid. Samples from each well were transferred to a 96-well plate and
the absorbance was measured at 595 nm on a microplate reader as an indirect
measure of cell number. Results were normalized to the value of initially plated
cells and presented as percentage of cells in each sample relative to control.
Quantitative real time one-step PCR and qPCR EMT array. Total RNA was
isolated using TriZol (Life technologies) and RNeasy Mini Kit (Qiagen). qPCR
primers and Brilliant III Ultra-Fast SYBR Green QRT-PCR Master Mix (Agilent
Technologies) with 50 ng RNA were used following the manufacturer’s instructions.
Fig. 6 Amoeboid behaviour enhances tumour formation, tumour progression and metastasis in vivo. a Schematic of in vivo experiment with 4599 cells
injected intradermally into NSG mice treated with ROCKi (25mg/kg GSK269962A) or control (5% DMSO) (n= 5 mice for control and n= 4 for ROCKi).
b Representative H&E images showing areas of TB, IF and local area of invasion into the dermis (distal invasive front (DIF)) of primary tumours derived
from (a). Dashed lines represent the boundary between tumour areas. Scale bar, 200 μm. c Representative images (left) and quantification (right) of
invading cells with co-staining of p-MLC2 (red) and ki-67 (green) at the DIF of control tumours from (a). Scale bar, 200 μm. Yellow arrows indicate ki-67
positive invading cells with p-MLC2 score 3 intensity. d–f Representative images (top) and quantification (bottom) of d melanoma cell shape score, e H-
score and percentage of cells with score intensity 0–3 for p-MLC2 staining and f ki-67 positive cells in primary tumours from (a). Scale bar, 100 μm; inset,
25 μm. g GSEA plots showing enrichment of proliferative and invasive gene signatures from Verfaillie study19 in A375M2 cells compared to A375M2 cells
treated with ROCKi (H1152 and Y27632) and blebbistatin or to A375P cells10. NES, normalized enrichment score; FDR, false discovery rate. h Tumour
growth curves of 4599 cells from (a). i Representative images (left) and QuPath mark-up (right) of mCherry staining and j quantification of invading cells
into the dermis in primary tumours derived from (a). Dashed lines represent the boundary between IF and DIF. Scale bar, 50 μm. k Representative images
(left) and quantification of tumour area (right) of spontaneous lung metastasis from (a). Scale bar, 1 mm. l, m Representative images of mouse lungs (left)
and quantification of tumour area (right) at the indicated times after tail vein injection of 4599 cells l pre-treated with ROCKi for 24 h orm without any pre-
treatment into NSG mice. Animals were systemically treated with ROCKi (n= 6 mice/group). Scale bar, 2 mm; inset, 500 μm. c Graphs show mean ± s.e.m.
d–f, j–m Box limits show 25th and 75th percentiles, the horizontal line shows the median, and whiskers show minimum and maximum range of values. d–f
One-way ANOVA with Benjamini, Krieger and Yekutieli correction. h, j Two-tailed t-test. k–m Two-tailed Mann–Whitney test. For all graphs, *p < 0.05, **p <
0.01, ***p < 0.001, ****p < 0.0001. The exact significant p values for *p, **p and ***p are provided in Supplementary Table 1. Schematics in this figure were
created using Servier Medical Art templates licensed under a Creative Commons Attribution 3.0 Unported License (https://smart.servier.com).
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GAPDH was used as loading control. The following qPCR primers from Sino Bio-
logical were used: WNT11 (HP101586), WNT5B (HP101843), ALDH1A1
(HP100088), OCT4 (HP101756). The following QuantiTect Primers from Qiagen
were used: GAPDH (QT00079247), ROCK1 (QT00034972), ROCK2 (QT00011165),
MYL9 (QT00072268), MYL12B (QT00075264), FZD7 (QT00213850), RYK
(QT00047292), PLCB1 (QT00038689), DAAM1 (QT00005579), ALDH1A3
(QT00077588), NANOG (QT01025850), JARID1B (QT00060648), CD44
(QT00073549), SOX2 (QT00237601), ALCAM (QT00026824).
Epithelial to mesenchymal transition (EMT) RT2 Profiler PCR Array (330231,
PAHS-090Z, Qiagen) was performed according to manufacturer’s instructions. For
that, 2 µg of total RNA were reverse-transcribed to cDNA using RT2 First Strand
Kit (Qiagen) and subjected to qPCR EMT array. Reactions were run on a
QuantStudio 7 Flex Real-Time PCR System (ThermoFisher Scientific). PCR array
was analysed using the web-based tool (https://dataanalysis.qiagen.com/pcr/
arrayanalysis.php) supplied by the manufacturer and gene expression was
normalized to housekeeping genes.
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Analysis of gene expression data from human databases. From the public
database GEO (Gene Expression Omnibus), Xu GSE840135 (31 primary and 52
metastatic melanomas), Riker GSE755334 (14 primary and 40 metastatic melano-
mas) and Kabbarah GSE4651733 (31 primary and 73 metastatic melanomas) series
were extracted. Data were normalized using GenePattern platform (https://www.
broadinstitute.org/cancer/software/genepattern).
Gene expression data and clinical information of human melanoma samples (70
primary and 319 metastatic melanomas) from The Cancer Genome Atlas (TCGA)
database were downloaded from Firehose (https://gdac.broadinstitute.org/). Only
TCGA samples with no neo-adjuvant treatment prior to tumour resection were
considered.
Gene enrichment analyses. Normalized gene expression microarray data of
amoeboid melanoma cells (GSE23764)10 was analysed by comparing amoeboid
A375M2 cells to more elongated and less contractile A375P cells or to A375M2
cells treated with ROCK1/2 inhibitors (H1152 and Y27632) or blebbistatin. Gene
sets for proliferative and invasive signatures from Verfaille19 and Hoek18 studies;
stem cell-like signatures and EMT processes were downloaded and analysed using
Gene Set Enrichment Analysis (GSEA) software68 (http://www.broadinstitute.org/
gsea/index.jsp) with the specific settings: permutations-1,000, permutation type-
gene set, metric for ranking genes-t-test. For single-sample Gene Set Enrichment
Analysis (ssGSEA), significantly enriched stem cell-like/EMT gene sets in amoe-
boid A375M2 cells were considered according to p-value < 0.05 and FDR < 0.25 in
at least 3 of the 4 comparisons performed. To calculate the gene-signature score in
each sample, we used ssGSEA Projection Software68,69 from GenePattern platform
(https://www.broadinstitute.org/cancer/software/genepattern). Heatmaps were
generated using MeV_4_9_0 software (http://mev.tm4.org/).
Network enrichment analysis of significantly downregulated genes in at least
one cell line also downregulated or with no expression changes in the other cell line
from qPCR EMT array was performed using Ingenuity Pathway Analysis (Qiagen).
Animal studies. All animals were maintained under specific pathogen-free con-
ditions and handled in accordance with the Institutional Committees on Animal
Welfare of the UK Home Office (The Home Office Animals Scientific Procedures
Act, 1986). All animal experiments were approved by the Ethical Review Process
Committees at Barts Cancer Institute, King’s College London and The Francis
Crick Institute and carried out under licences from the Home Office, UK. All mice
were obtained from Charles River UK. Mice used were 6–12 weeks old. Animals
were housed in groups of 4–5 mice per cage with access to food and water ad
libitum. Mice were maintained on an alternating 12 h light-dark cycle, with con-
trolled room temperature (21 ± 1 °C) and relative humidity (40–60 %).
For tumour initiation assays with pre-treated A375M2 and B16F10 cells, prior
to injection cells were pre-treated in vitro with ROCK1/2 inhibitors (5 µM H1152,
1 µM or 5 µM GSK269962A) for 5 days, with fresh drug added every day. Then 1 ×
106 A375M2 cells or 2 × 105 B16F10 cells were mixed in 100 µl of Growth Factor
Reduced Matrigel (356230, Corning), and injected subcutaneously into female
NOD/SCID/IL2Rγ− (NSG) mice (A375M2) or C57BL/6 J mice (B16F10). Mice
were not treated during the course of the experiment.
For limiting dilution assays, 5 × 105, 5 × 104, 1 × 104 or 5 × 103 cells (A375M2/
A375P cells, stable shFZD7#1/shDAAM1#1/shControl WM1361 cells and stable
shDAAM1#1/shControl A375M2 cells) were mixed in 100 µl of Growth Factor
Reduced Matrigel (356230, Corning) and injected subcutaneously into female NSG
mice. Tumour growth was assessed 3 weeks after injection. The tumour-initiating
frequency (TIF) was estimated by ELDA22 using the bottom 20th percentile of
tumour size in each experiment as the limiting threshold for positive growth. Only
tumours above this threshold were considered.
For the orthotopic experiment using 4599 cells, 2 × 105 4599 cells stably
expressing hNIS-mCherry (4599.hNIS-mCherry) in 30 µl PBS were injected
intradermally into male NSG mice. Tumours were allowed to establish and
treatment started at day 11 when mean tumour volume was 20 mm3. Drug
administration (25 mg/kg GSK269962A dissolved in 5% DMSO or vehicle 5%
DMSO) was performed daily by oral gavage.
For all the above tumour models, tumour size was monitored and determined
by caliper measurements and calculated as tumour volume (mm3)= length ×
width × height × 0.52. At the end of experiments, prior to dissection tumours were
measured; or dissected tumours were weighed. Tumours were formalin-fixed and
paraffin-embedded (FFPE) for immunohistochemical analysis.
For experimental metastasis assays, 1 × 106 stable shDAAM1 and shControl
WM1361 cells in 100 µl PBS were injected into the tail vein of NSG mice (matched
male and female). Mice were sacrificed after 30 min (to show that equal cell
numbers reach the lung), 24 h and 3 weeks, and then lungs were washed, fixed in
4% formaldehyde for 16 h and examined for fluorescent signal (GFP from shRNA
constructs) under a Zeiss LSM 510 Meta confocal microscope (Carl Zeiss). 20–25
images per mouse lung were analysed, and lung retention was represented as
percentage of fluorescence area per mouse lung.
For experimental metastasis assays using 4599 cells, 4 × 105 cells pre-treated
in vitro with 5 µM GSK269962A for 24 h were injected in 200 µl PBS into the tail
vein of NSG female mice. Mice were treated daily (25 mg/kg GSK269962A
dissolved in 5% DMSO or vehicle 5% DMSO) by oral gavage. Mice were sacrificed
after 30 min and 6 days, and then lungs were washed, fixed and examined by
immunohistochemistry. Similarly, 4 × 105 4599 cells without any pre-treatment in
200 µl PBS were injected into the tail vein of NSG female mice and animals were
treated daily (25 mg/kg GSK269962A dissolved in 5% DMSO or vehicle 5%
DMSO) by oral gavage for 12 days.
Immunohistochemistry
Case selection. Two tissue microarrays, including FFPE biopsies of 53 human
primary melanomas and 45 metastases (Supplementary Tables 2 and 3) were
included in the case series. Each biopsy was represented by two cores (1 mm
diameter) from the tumour body (TB) and two cores from the invasive front (IF)
areas. The IF was defined as melanoma cells with at least 50% contact with the
matrix as previously described7,10,12. Tumours were classified following the most
recent World Health Organization criteria. Tumour samples were processed by
IRBLleida (PT17/0015/0027) and HUB-ICO-IDIBELL (PT17/0015/0024) Biobanks
integrated in the Spanish National Biobank Network and Xarxa de Bancs de
Tumors de Catalunya following standard operating procedures with the appro-
priate approvals from the Ethics and Scientific Committee. Samples were collected
with specific informed consent, in accordance with the Helsinki Declaration.
Whole sections from subcutaneous tumours (A375M2/A375P tumours,
shControl/shFZD7/shDAAM1 WM1361 tumours and shControl/shDAAM1
A375M2 tumours from limiting dilution assays), from intradermal tumours (4599
cells) and mice lungs from tail vein metastasis assays (4599 cells) were included.
Melanospheres from serial sphere passages were also included. Agar pellets were
generated with spheres from every passage. Spheres were collected gently and spun
down at 300 × g for 10 min. Pellets were washed twice with PBS and embedded in
50 µl 3% agar. Finally, agar pellets were embedded in paraffin using standards
methods for immunohistochemical analysis.
Experimental procedure. All tissue samples were FFPE, sectioned (3–4 μm-thick)
and dried for 1 h at 65 °C. Next, tissue samples were subjected to deparaffinization,
rehydration and heat-induced epitope retrieval using a Biocare Decloaking
Chamber (DC2012) at 110 °C for 6 min in the corresponding unmasking solution
(Supplementary Table 5). The endogenous peroxidase was blocked with dual
endogenous enzyme-blocking reagent (#S2003, Agilent) for 10 min. Reagents were
incubated at room temperature in a humidified slide chamber. Detailed informa-
tion about the antibodies, dilutions and conditions used for the immunohisto-
chemical stainings are specified in Supplementary Table 5. All the stainings were
counterstained with Haematoxylin.
Imaging and scoring. Morphologic analysis of tumour tissues was performed on
haematoxylin- and eosin-stained (H&E) sections as previously described10. Cell
shape was graded from 0 to 3 (0= round, 1= ovoid, 2= elongated and 3=
spindly) and a score was assigned as follows: cell shape score= ((percentage of cells
[%] shape 0 × 0)+ (% shape 1 × 1)+ (% shape 2 × 2)+ (% shape 3 × 3)), with
values ranging from 0 (all cells round) to 300 (all cells spindle). Using consecutive
Fig. 7 Analysis of the invasive front of human primary melanomas. a–i Representative images (left) and quantification (right) of a melanoma cell shape
score, b H-score of p-MLC2 staining, c ki-67 positive cells, H-score of d DAAM1, e WNT11, f WNT5B, g ALDH1A1, h CD44 and i NANOG staining in
matched TB and IF from primary melanomas. j Principal component analysis (PCA) based on the expression of amoeboid (cell shape and p-MLC2),
proliferative (ki-67), non-canonical Wnt pathway (WNT11, WNT5B and DAAM1) and cancer stem cell-related (ALDH1A1, CD44 and NANOG) markers
assessed by immunohistochemistry in matched TB and IF from primary melanomas. Percentage of variation explained by each component is given in the
axis labels. k, l Kaplan–Meier survival curves of k overall survival and l disease-free survival according to ALDH1A1 protein expression in the IF from our
cohort of primary melanomas. ALDH1A1 expression was categorized as low or high using the median expression. a–l 53 primary melanomas. a, e–i Scale
bar, 100 μm; inset, 50 μm. b–d Scale bar, 300 μm. a–i Box limits show 25th and 75th percentiles, the horizontal line shows the median, and whiskers show
the minimum and maximum range of values. a, b, d–f Two-tailed paired t-test. c, g–i Two-tailed Wilcoxon test. j Scatter plot showing principal components
1 (PC1) and 2 (PC2). k, l Log-rank test. Human schematic in this figure was created using Servier Medical Art templates licensed under a Creative
Commons Attribution 3.0 Unported License (https://smart.servier.com).
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sections, IHC staining for all the markers was graded semiquantitatively by con-
sidering the percentage and intensity of the staining. A histologic score (H-score)
was obtained from each sample, and values ranged from 0 (no immunoreaction) to
300 (maximum immunoreactivity). The score was obtained by applying the fol-
lowing formula, H-score= 1 × (% light staining)+ 2 × (% moderate staining)+
3 × (% strong staining). WNT11, WNT5B, CD44, NANOG, OCT4, ALDH1A1 and
ALDH1A3 stainings were scored blind and a staining H-score was provided for
each section. Representative pictures according to mean H-score were imaged
using iScope microscope (IS.1159EPLi, Euromex) and ImageFocus 4.0 (Euromex)
software. For p-MLC2, ki-67, FZD7 and DAAM1 stainings, whole section images
(WSI) were scanned using NanoZoomer S210 slide scanner (Hamamatsu). Staining
quantification was performed with QuPath 0.1.2 software70. Positive cell detection
was performed, and three different thresholds were applied according to the
intensity scores (0, 1, 2 and 3). Next, software was trained creating random tree
classification algorithms combined with intensity information in order to differ-






























































































































































































































NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-18951-2 ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:5315 | https://doi.org/10.1038/s41467-020-18951-2 | www.nature.com/naturecommunications 17
was graded semiquantitatively by considering the percentage and intensity of the
staining, and H-score values were calculated as described above. Furthermore, to
show spatial correlation between different markers (ALDH1A1, CD44, p-MLC2,
DAAM1 and ki-67), hotspots maps were created using the optical density mean
(OD mean)—Chanel 2: VIP stain intensity in QuPath. For co-localization analysis,
images for p-MLC2 and ki-67 markers were aligned in FIJI v1.52p using TrackEM2
module. Next, colour deconvolution was performed using AEC-Haematoxylin
vectors and a composite was created using channel-2 (red) for each staining. The
composite was adjusted inverting the LUT for each marker and was given a
pseudocolour. mCherry staining was performed for quantification of invading cells
in primary tumours from experiments using 4599 cells. WSI were scanned using
NanoZoomer S210 slide scanner (Hamamatsu). mCherry analysis was performed
using QuPath software: an invasive area was delimited underneath the tumour
invasive front and positive cells were counted using the positive cell detection plug-
in. Assessment of lung colonization assays with 4599 cells was performed on H&E
WSI of lungs using QuPath software. Several supervised annotations were per-
formed in each study identifying tumour, normal tissue and whitespace areas. Next,
pixel classifier was performed in the whole-image for all the cases using random-
tree classification and low resolution.
Statistical analysis. Unpaired t test, Mann–Whitney’s test, paired t-test, Wilcoxon
test, one-way ANOVA with Dunnett or Tukey post hoc test or Benjamini, Krieger
and Yekutieli correction, and Kruskal–Wallis with Dunn’s multiple comparison test
were performed using GraphPad Prism (GraphPad Software, Inc). Principal Com-
ponent Analysis, survival curves estimation based on the Kaplan–Meier method and
log-rank test were performed using SPSS Statistics (IBM). Limiting dilution assays
were analysed using ELDA software (http://bioinf.wehi.edu.au/software/elda/)22.
Data were plotted as graphs showing mean ± standard error of the mean (s.e.m.); or
boxplots where box limits show 25th and 75th percentiles, the horizontal line shows
the median, and whiskers show minimum and maximum range of values as indi-
cated in figure legends. P values were calculated using two-tailed tests. P values of less
than 0.05 were considered statistically significant. In Figure legends, “n” means
number of independent biological experiments unless otherwise stated.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Gene expression datasets re-analysed in this study are available from NCBI GEO under
accession numbers: GSE23764, GSE8401, GSE7553 and GSE46517. Uncropped
immunoblot scans for representative images displayed in the figures are shown in Source
data. All other relevant data supporting the findings of this study are available within the
article and its Supplementary information and from the corresponding author on
reasonable request. Source data are provided with this paper.
Code availability
No custom codes were used in this study. All codes are indicated in the appropriate
Methods sections and references.
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